
Chris Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2428105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rapid Adaptation of Cancer Education in Response to the COVID-19 Pandemic: Evaluation of a Live Virtual Statistics and Research Skills Workshop for Oncology Trainees. Journal of Cancer Education, 2022, 37, 905-910.	1.3	8
2	Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. Practical Radiation Oncology, 2022, 12, e201-e206.	2.1	8
3	Nutritional status and skeletal muscle status in patients with head and neck cancer: Impact on outcomes. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2187-2198.	7.3	30
4	Outcomes for elderly patients 75 years and older treated with curative intent radiotherapy for mucosal squamous cell carcinomas of the head and neck. Head and Neck, 2020, 42, 25-32.	2.0	9
5	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq1 1 0.78 2020, 21, 1331-1340.	84314 rgB7 10.7	Г /Overlock 197
6	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet, The, 2020, 396, 1422-1431.	13.7	224
7	Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1172-1178.	0.8	36
8	Rolling out RapidPlan: What we've learnt. Journal of Medical Radiation Sciences, 2020, 67, 310-317.	1.5	2
9	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	10.7	109
10	Best Evidence to Best Practice: Implementing an Innovative Model of Nutrition Care for Patients with Head and Neck Cancer Improves Outcomes. Nutrients, 2020, 12, 1465.	4.1	23
11	Resisting the Far-Right: Indigenous Perspectives, Community Arts and Story-Based Strategy. Cosmopolitan Civil Societies, 2019, 11, 55-73.	0.4	0
12	Screening the secondâ€ŧrimester fetal heart in women with an increased body mass index using threeâ€dimensional volume sweep. Australasian Journal of Ultrasound in Medicine, 2018, 21, 45-48.	0.6	1
13	Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals in NSW (2000–2008): a linked data population-based cohort study. BMJ Open, 2014, 4, e004551.	1.9	47
14	Risk of recurrence, subsequent mode of birth and morbidity for women who experienced severe perineal trauma in a first birth in New South Wales between 2000 –2008: a population based data linkage study. BMC Pregnancy and Childbirth, 2013, 13, 89.	2.4	34
15	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 2013, 81, 422-427.	2.0	51
16	Trends and risk factors for severe perineal trauma during childbirth in New South Wales between 2000 and 2008: a population-based data study. BMJ Open, 2013, 3, e002824.	1.9	25
17	Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 595-605.	6.3	469
18	Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4701-4708.	3.6	72

CHRIS BROWN

#	Article	IF	CITATIONS
19	Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: a population-based descriptive study. BMJ Open, 2012, 2, e001723.	1.9	93
20	Corrigendum to "Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis―[Eur J Cancer 47 (12) (2011) 1826–1836]. European Journal of Cancer, 2012, 48, 407.	2.8	0
21	Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. Lung Cancer, 2011, 72, 213-218.	2.0	17
22	Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 2011, 47, 1826-1836.	2.8	17
23	Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. Journal of Clinical Neuroscience, 2011, 18, 1444-1448.	1.5	85
24	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, 2011, 67, 519-525.	2.3	9
25	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 2011, 103, 1338-1342.	6.3	33
26	Population Case-Control Study of Cerebral Palsy: Neonatal Predictors for Low-Risk Term Singletons. Pediatrics, 2011, 127, e667-e673.	2.1	18
27	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 2010, 28, 3323-3329.	1.6	500